Vaxcyte Inc. Common Stock vs TAL Education Group American Depositary Shares — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while TAL Education Group American Depositary Shares trades at $12.44 (market cap $7.01B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and TAL Education Group American Depositary Shares is more actively traded (3,223,678 versus 2,644,694). Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and TAL Education Group American Depositary Shares for 3 Days on average.
| PCVX | TAL | |
|---|---|---|
Market Cap | $10.51B | $7.01B |
Volume | 2,644,694 | 3,223,678 |
Sector | Health | Consumer Staples |
52-Week High | $73.82 | $12.91 |
52-Week Low | $40.32 | $8.95 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $9.14B | $4.54B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TAL Education Group trades at $12.64, down 0.63% with strong bullish technical signals from moving averages. The company demonstrates impressive fundamental strength with 28.43% net income margin and 23.72% ROE, supported by three consecutive earnings beats. Revenue growth accelerated from $2.25B in 2025 to $3.2B in 2026, while profitability surged from $85M to $907M net income. Analyst consensus shows 42.86% buy ratings with price targets suggesting 27.63% upside potential.
TAL presents a compelling investment case with strong earnings momentum and attractive valuation at 7.92 P/E. However, investors face risks from China's regulatory environment and the company's negative cash flow position of -$465.75M in 2025. The technical setup supports near-term upside with key resistance at $13 and support at $12, while institutional sentiment remains positive despite cash flow concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →TAL Education Group provides smart learning solutions in China. Its offerings combine teaching content, technology, and learning services through various online and offline formats.
Read more on TAL →